Linksbridge

Linksbridge expands the capacity of NGOs, IGOs, and nonprofits to improve human lives.

More than a consultancy, more than a research and advisory firm, and more than a creative agency – Linksbridge combines excellence in each of these professional services with a passion for effecting change

05/28/2026

Eli Lilly made a power move back into vaccines and infectious diseases this week, scooping up three vaccine developers focused on chlamydia, Epstein-Barr virus, staph and other pathogens. More on this update and other pharma news important to global health in this week's highlights.

Lilly makes $4B play for infectious disease vaccines Eli Lilly is back in the vaccines game. The company announced Tuesday that it will shell out close to $4 billion to acquire a trio of companies developing vaccines for viral pathogens linked to long-term neurological and oncological risk, and for

05/21/2026

Serum Institute of India says it needs less than a month to manufacture doses of an experimental vaccine ready for testing against the rare species of Ebola spreading in DRC and Uganda.

More on efforts to combat Bundibugyo virus and other pharma news important to global health in this week's highlights.

Ebola outbreak: race for vaccines and drugs begins As a rare species of Ebola spreads in DRC and Uganda, Oxford University and the Serum Institute of India (with support from CEPI) have entered an “emergency response arrangement” to develop and manufacture an investigational vaccine ready for te...

05/14/2026

Africa CDC's first African Pooled Procurement Mechanism (APPM) tender for essential medicines for reproductive, maternal and newborn health achieved 30%-90% lower prices compared with member state benchmarks. More on this update and other pharma news important to global health in this week's highlights.

Study: Mosquirix significantly reduced child deaths Introducing Bharat Biotech and GSK’s Mosquirix (RTS,S) malaria vaccine in routine immunization programs in Ghana, Kenya and Malawi averted “about one in eight deaths” among young children over a four-year period. That’s according to study r...

04/30/2026

Last week's World Malaria Day generated a flurry of pharma news important to global health, including WHO's prequalification of Coartem Baby (the Novartis/MMV infant antimalarial), India's sign-off on Phase 3 trials of Zydus Lifesciences' oral antimalarial zintrodiazine, Serum Institute of India's licensing deal with Oxford University for a blood-stage vaccine, and more.

Coartem Baby wins WHO PQ WHO has prequalified Coartem Baby, the newborn-and-infant antimalarial jointly developed by Novartis and Medicines for Malaria Ventures (MMV). Novartis trumpeted the news last week, just ahead of World Malaria Day.

04/23/2026

Armed with a fresh $108 million funding boost, South Africa-based Biovac is gearing up to build the continent's first end-to-end multivaccine manufacturing facility in Cape Town. This week's issue spotlights Biovac's ambitious push, Switzerland's newly unredacted Covid vaccine contracts, data from an early-stage chikungunya mAb trial, and more.

Biovac nabs $108M for end-to-end vaccine manufacturing Africa’s first end-to-end multivaccine manufacturing facility is coming to Cape Town. The E.

04/16/2026

A new effort to expand access to Gilead's twice-yearly PrEP drug to an additional 1 million people over the next three years doesn't go far enough, argue AVAC and Access Bridge. Lenacapavir needs to reach more than 5 million people per year to have "real impact, build a sustainable market, and drive prices down even further."

More on this development and other pharma news important to global health in this week's highlights 👇

U.S.

04/09/2026

This week's issue highlights challenges along the path from drug innovation to patient access:

» Gilead's refusal to sell lenacapavir to MSF shows how a manufacturer's access framework can fall short, leaving people who need HIV PrEP without it.

» Meanwhile, efforts to push Merck to commit to generic licensing for its promising oral PrEP candidate before it reaches the market aim to avoid the same post-approval access scramble.

» Antibiotic developer Iterum's collapse demonstrates a different kind of obstacle: even when a drug is approved and available, weak commercial incentives can still choke off access.

MSF blasts Gilead over lenacapavir sales Médecins Sans Frontières (MSF) is publicly slamming Gilead for its “outright refusal” to sell Yeztugo (lenacapavir) to the humanitarian organization. In an open letter last week, MSF faulted the drugmaker’s “unconscionable” restrictions on access ...

04/02/2026

Pharmaniaga has landed a $70M, three-year contract to supply human insulin to Malaysia’s public hospitals, becoming the first local producer and potentially unseating supplier incumbents Biocon and Novo Nordisk.

This week’s highlights cover the contract, vaccine R&D updates, the latest on the Pandemic Treaty’s Pathogen Access and Benefit Sharing annex, and other pharma news important to global health.

Pharmaniaga wins Malaysia human insulin contract Pharmaniaga has scored its first contract to supply human insulin to Malaysian government hospitals, The Edge reported Wednesday. The three-year contract—worth about $70 million—makes the Shah Alam-based manufacturer the first local human insulin ...

03/26/2026

The vaccine microarray patch field just got smaller. Needle-free vaccine specialist Vaxess—which raised millions for Covid, flu, measles-rubella and polio vaccines R&D—is pivoting to the lucrative GLP-1 space. More on this update and other pharma news important to global health in this week's highlights.

Vaxess abandons vaccines for GLP-1s Armed with a new name and $50 million in Series C funding, microarray patch specialist Vaxess—now Terrestrial Bio—is officially pivoting from vaccines to GLP-1s. That’s according to an Endpoints News exclusive interview with the company’s CEO, who said the...

03/19/2026

In this week's highlights, we cover a successful first-in-human trial of Moderna's Nipah virus vaccine. The jab—co-developed with NIAID—is the first to clinically test a two-pronged approach: targeting both the attachment protein (which most Nipah candidates focus on) and the fusion protein (which may provide broader protection).

Vaccine R&D: Nipah, chronic hep B and dengue news An mRNA-based Nipah vaccine co-developed by Moderna and the U.S.

Address

808 Fifth Avenue North
Seattle, WA
98109

Website

http://linksbridge.com/

Alerts

Be the first to know and let us send you an email when Linksbridge posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Linksbridge:

Shortcuts

Featured

Trücup coffee roasters

Want your business to be the top-listed Business in Seattle?